1. Home
  2. IMTX vs MNKD Comparison

IMTX vs MNKD Comparison

Compare IMTX & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immatics N.V.

IMTX

Immatics N.V.

HOLD

Current Price

$9.88

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo MannKind Corporation

MNKD

MannKind Corporation

SELL

Current Price

$4.40

Market Cap

1.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
IMTX
MNKD
Founded
N/A
1991
Country
Germany
United States
Employees
407
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.2B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
IMTX
MNKD
Price
$9.88
$4.40
Analyst Decision
Strong Buy
Buy
Analyst Count
6
8
Target Price
$19.00
$8.69
AVG Volume (30 Days)
376.9K
4.8M
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$348,966,000.00
Revenue This Year
N/A
$35.81
Revenue Next Year
$25.91
$11.89
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.23
52 Week Low
$5.05
$2.23
52 Week High
$12.41
$6.51

Technical Indicators

Market Signals
Indicator
IMTX
MNKD
Relative Strength Index (RSI) 49.91 69.91
Support Level $9.61 $3.77
Resistance Level $10.64 $6.12
Average True Range (ATR) 0.50 0.22
MACD 0.09 0.03
Stochastic Oscillator 70.90 97.24

Price Performance

Historical Comparison
IMTX
MNKD

About IMTX Immatics N.V.

Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: